ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Independent risk factors for refractory mycoplasma pneumoniae pneumonia in children: a multivariate analysis.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the risk factors for refractory Mycoplasma pneumoniae pneumonia (RMPP) in children.
methodsChildren with Mycoplasma pneumoniae pneumonia who were treated in our hospital from January 1, 2024 to June 1, 2025 were retrospectively collected and divided into the refractory Mycoplasma pneumoniae pneumonia group with 144 cases and the general Mycoplasma pneumoniae pneumonia (GMPP) group with 161 cases according to the occurrence of RMPP. The clinical data and serological indicators of the two groups were compared using the t-test, χ²-test and Logistic regression analysis.
resultLeukocyte count (8.62 ± 4.48 vs. 9.84 ± 1.01, P = 0.002), C-reactive protein (21.64 ± 14.76 vs. 26.61 ± 6.71, P < 0.001), D-dimer (0.72 ± 0.10 vs. 1.08 ± 0.60, P < 0.001), lactate dehydrogenase (281.05 ± 80.22 vs. 326.02 ± 43.92, P < 0.001) and neutrophil-to-lymphocyte ratio (NLR, 3.11 ± 2.11 vs. 4.84 ± 0.95, P < 0.001) in the RMPP group were significantly higher than those in the GMPP group. The Clinical Pulmonary Infection Score (CPIS, OR = 2.617, 95%CI:1.603-4.273), D-dimer (OR = 9.891, 95%CI:3.848-25.426), NLR (OR = 1.865, 95%CI:1.490-2.336), presence of pulmonary rales (OR = 5.265, 95%CI:2.305-12.026), abnormal chest imaging findings (P = 0.005), complicated infections (P < 0.001) and positive drug-resistant gene loci (OR = 14.023, 95%CI:5.712-34.426) were identified as independent influencing factors for RMPP infection. NLR yielded the highest area under the curve (AUC) for predicting RMPP infection with an AUC of 0.836 (95%CI:0.788-0.885), followed by the CPIS with an AUC of 0.700 (95%CI:0.640-0.759) and D-dimer with an AUC of 0.691 (95%CI:0.620-0.762).
conclusionThe CPIS, D-dimer, NLR, presence of pulmonary rales, abnormal chest imaging findings, complicated infections and positive drug-resistant gene loci are independent influencing factors for RMPP infection, and vigilance for the development of RMPP is warranted in the presence of these factors.
Indexed as
Identifiers
42527760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.